Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers

Brain

Volumn 134, Issue 1, 2011, Pages 293-300

  Knight, William D ^a   Okello, Aren A ^b   Ryan, Natalie S ^a   Turkheimer, Federico E ^b   Rodríguez Martinez De Llano, Sofia ^b   Edison, Paul ^b   Douglas, Jane ^a   Fox, Nick C ^a   Brooks, David J ^b   Rossor, Martin N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; genetics; PET imaging

Indexed keywords

PITTSBURGH COMPOUND B; PRESENILIN 1;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTERIOR CINGULATE; ARTICLE; CEREBELLUM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DRUG UPTAKE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PONS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; SCHOOL CHILD; THALAMUS;

EID: 78650701257     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq310     Document Type: Article

References (55)

1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-17.
2. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-7.
3. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Human Genet 1999; 65: 664-70.
4. Clark RF, Hutton M, Fuldner RA, Froelich S, Karran E, Talbot C, et al. The structure of the Presenilin-1 (S182) gene and identification of 6 novel mutations in early-onset AD families. Nature Genet 1995; 11: 219-22.
5. Cruts M, Van Duijn CM, Backhovens H, Van den BM, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 1998; 7: 43-51.
6. Dermaut B, Kumar-Singh S, De Jonghe C, Cruts M, Lofgren A, Lubke U, et al. Cerebral amyloid angiopathy is a pathogenic lesion inAlzheimer's disease due to a novel presenilin 1 mutation. Brain 2001; 124: 2383-92.
7. Desikan RS, Fischl B, Cabral HJ, Kemper TL, Guttmann CR, Blacker D, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71: 819-25.
8. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8.
9. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebro-spinal fluid A beta(42) in humans. Ann Neurol 2006; 59: 512-9.
10. Folstein MF, Folstein SE, Mchugh PR. Mini-mental state - practical method for grading cognitive state of patients for clinician. J Psychiatric Res 1975; 12: 189-98.
11. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
12. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-500.
13. Godbolt AK, Beck JA, Collinge J, Garrard P, Warren JD, Fox NC, et al. A presenilin 1 R278I mutation presenting with language impairment. Neurology 2004; 63: 1702-4.
14. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-10.
15. Gustafson L, Brun A, Englund E, Hagnell O, Nilsson K, Stensmyr M, et al. A 50-year perspective of a family with chromosome-14-linked Alzheimer's disease. Hum Genet 1998; 102: 253-7.
16. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19: 224-47.
17. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-45.
18. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. C-II PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-80.
19. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. J Neurol Neurosurg Psychiatry 2002; 73: 219.
20. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-34.
21. Jorgensen P, Bus C, Pallisgaard N, Bryder M, Jorgensen AL. Familial Alzheimer's disease co-segregates with a Met146I1e substitution in presenilin-1.Clin Genet 1996; 50: 281-6.
22. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80.
23. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [C-11]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-6.
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
25. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007; 27: 6174-84.
26. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [C-11]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008; 131: 1845-53.
27. Kyriakides T, Silbert PL, Kakulas BA. Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. Clin Neuropathol 1994; 13: 71-6.
28. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 2006; 253: 139-58.
29. Larner AJ, du Plessis DG. Early-onset Alzheimer's disease with presenilin-1 M139V mutation: clinical, neuropsychological and neuro-pathological study. Eur J Neurol 2003; 10: 319-23.
30. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
31. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, et al. Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway. Neurology 1996; 46: 406-12.
32. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-15.
33. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thio-flavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 2005; 280: 7677-84.
34. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001; 158: 2165-75.
35. Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, et al. Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry 2002; 52: 907-10.
36. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995; 19: 541-7.
37. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
38. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
39. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Na? gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-60.
40. O'Riordan S, McMonagle P, Janssen JC, Fox NC, Farrell M, Collinge J, et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59: 1108-10.
41. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
42. Ramirez-Duenas MG, Rogaeva EA, Leal CA, Lin C, Ramirez-Casillas GA, Hernandez-Romo JA, et al. A novel Leu171Pro mutation in presenilin-1 gene in a Mexican family with early onset Alzheimer disease. Ann Genet 1998; 41: 149-53.
43. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, et al. Carbon 11-labeled Pittsburgh Compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008; 65: 540-4.
44. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006; 5: 828-34.
45. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
46. Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009; 54: 347-57.
47. Takao M, Ghetti B, Hayakawa I, Ikeda E, Fukuuchi Y, Miravalle L, et al. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in aJapanese family: presenile dementia and parkinsonism are associatedwith cotton wool plaques in the cortex and striatum. Acta Neuropathol2002; 104: 155-70.
48. Thal DR, Rub U, Orantes M, Braak H. Phases of Ab-deposition in thehuman brain and its relevance for the development of AD. Neurology2002; 58: 1791-800.
49. Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S,Bormans G, et al. Alzheimer dementia caused by a novel mutationlocated in the APP C-terminal intracytosolic fragment. Human Mutat2006; 27: 888-96.
50. Turkheimer FE, Smith CB, Schmidt K. Estimation of the number of 'true"null hypotheses in multivariate analysis of neuroimaging data.NeuroImage 2001; 13: 920-30.
51. Tysoe C, Whittaker J, Xuereb J, Cairns NJ, Cruts M, Van Broeckhoven C,et al. A presenilin-1 truncating mutation is present in two cases withautopsy-confirmed early-onset Alzheimer disease. Am J Human Genet1998; 62: 70-6.
52. Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, et al. Variant Alzheimer disease with spastic paraparesis: Neuropathological phenotype. J Neuropathol Exp Neurol 2001; 60: 483-92.
53. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. A beta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-97.
54. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-68.
55. Yasuda M, Maeda K, Ikejiri Y, Kawamata T, Kuroda S, Tanaka C. A novel missense mutation in the presenilin-1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy. Neurosci Lett 1997; 232: 29-32.